

**Date: 26.09.2024**

**To**

**Assistant Vice President, Surveillance  
National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051**

**NSE Code: MEDICAMEQ**

**Subject: Reply to the Clarification sought on Price Movement**

This is with reference to communication received from NSE vide email dated September 25, 2024 Ref No.: NSE/CM/Surveillance/14799 seeking clarification in significant price moment, we bring to the kind notice of the Exchange that there are no reportable events, information etc., that have a bearing on the operation/performance of the Company including price sensitive information which may result in the increase in the Prices of the shares of the Company under Regulation 30 of SEBI (LODR) Regulations, 2015.

The increase in the share price is purely market driven and the current market conditions; the management of the Company is in no way connected with such increase in Price of shares.

The Company is compliant on the stock price movements. However, the Company will continue to make appropriate disclosures, in accordance with applicable regulations, as and when any disclosable event occurs.

Kindly take the same on your records and oblige.

Thanking You

Yours truly,  
**For Medicamen Biotech Limited**

**Parul Choudhary  
Company Secretary & Compliance Officer  
ACS: 44157**